日本全国队列分析:粒子治疗转移性肝肿瘤的疗效与安全性
日本放射肿瘤学会基于2016—2019年全国多机构前瞻性队列的登记数据,回顾性分析了322例接受质子束或碳离子放疗的转移性肝肿瘤患者。2年和5年总生存率分别为55.7%和32.8%,中位生存时间28.6个月;2年和5年局部控制率分别为74.3%和66.4%,≥3级晚期毒性发生率为3.1%,未观察到5级毒性。单发病灶及结直肠癌或乳腺癌患者生存更优,肿瘤<5 cm者在结直肠癌、胰腺癌、胃癌和食管癌中生存也更好。
要点
- 322例转移性肝肿瘤患者接受粒子治疗,2年和5年OS率分别为55.7%和32.8%,MST为28.6个月。
- 2年和5年局部控制率分别为74.3%和66.4%,≥3级晚期毒性发生率为3.1%,无5级毒性。
- 单发病灶及结直肠癌或乳腺癌患者生存更优,肿瘤<5 cm在部分癌种中亦与更好生存相关。
核心结论
- 粒子治疗预期可为转移性肝肿瘤提供优良的局部控制和较低的严重不良事件发生率。
- 尤其在结直肠癌和乳腺癌病例中观察到有希望的OS率,提示粒子治疗可能为经过仔细筛选的患者带来生存获益。
研究设计与样本
- 本研究为日本放射肿瘤学会开展的全国多机构前瞻性队列,并利用登记数据对转移性肝肿瘤进行回顾性队列分析。
- 纳入2016年至2019年间接受质子束治疗和碳离子放射治疗的患者,共322例符合条件者纳入分析。
- 粒子治疗剂量方案根据肿瘤位置而不同。
主要发现
- 322例患者2年和5年估计OS率分别为55.7%和32.8%,中位生存时间为28.6个月。
- 单发病灶患者,尤其是结直肠癌或乳腺癌患者,生存率高于多发病灶患者。
- 肿瘤<5 cm的患者,尤其在结直肠癌、胰腺癌、胃癌和食管癌中,生存优于肿瘤≥5 cm者。
- Cox比例风险模型显示结直肠癌和胰腺癌最大肿瘤直径差异有统计学意义(均P = .002),乳腺癌病灶数量差异有统计学意义(P = .02)。
- 2年和估计5年PFS率分别为23.5%和12.8%,MST为9个月;2年和估计5年LC率分别为74.3%和66.4%。
关键数值与推荐
- 复发见于223例患者,其中仅局部复发43例,仅远处复发163例,两者兼有17例。
- 不良事件发生率为3.1%,主要为皮炎和肝胆疾病,未观察到5级毒性。
- 乳腺癌单发病灶或未接受同期全身治疗的患者亚组分析中,MST超过5年。
临床怎么用
- 对于经过筛选的转移性肝肿瘤患者,粒子治疗可作为提供优良局部控制和低严重不良事件率的治疗选择。
- 单发病灶、结直肠癌或乳腺癌患者,以及部分癌种中肿瘤<5 cm者,可能从粒子治疗中获得更优生存。
局限性
- 本研究为利用登记数据的回顾性队列分析。
- 粒子治疗剂量方案根据肿瘤位置而不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the efficacy and safety of particle therapy (PT) for treating metastatic liver tumors. Conducted by the Japanese Society for Radiation Oncology, this nationwide, multi-institutional analysis examined PT outcomes, including overall survival (OS) rates and adverse events, to determine its potential as a treatment option for patients with limited liver metastases. METHODS AND MATERIALS: This nationwide, multi-institutional prospective cohort included patients treated with proton beam therapy and carbon-ion radiation therapy between 2016 and 2019. This is a retrospective cohort study utilizing registry data of metastatic liver tumors. PT dose schedules used varied based on tumor location. Outcomes assessed included OS, progression-free survival (PFS), local control (LC), and late treatment-related toxicities of grade ≥3. RESULTS: Among 322 eligible patients, the 2- and 5-year estimated OS rates were 55.7% and 32.8%, respectively, with a median survival time (MST) of 28.6 months. Patients with single lesions, particularly those with colorectal or breast cancer, demonstrated higher survival rates than those with multiple lesions. Patients with smaller tumors (<5 cm), especially in colorectal, pancreatic, gastric, and esophageal cancers, also showed improved survival compared with those with tumors ≥5 cm. Cox proportional hazards model analysis showed significant difference in maximal tumor diameter in colorectal cancer and pancreatic cancer (both P = .002) and number of lesions in breast cancer (P = .02). In a condition-specific subgroup analysis, MST exceeded 5 years in patients with breast cancer who had a single lesion or who did not receive concurrent systemic therapy. The 2- and estimated 5-year PFS rates were 23.5% and 12.8%, respectively, with MST of 9 months. The 2- and estimated 5-year LC rates were 74.3% and 66.4%, respectively. Recurrence was observed in 223 patients (local only, 43; distant only, 163; both, 17). Adverse events occurred in 3.1% of patients, primarily dermatitis and hepatobiliary disorders, with no grade 5 toxicities observed. CONCLUSIONS: PT is expected to provide excellent LC and low rates of serious adverse events for metastatic liver tumors. Promising OS rates, particularly in cases of colorectal and breast cancer, suggest that PT offers a survival advantage to carefully selected patients.
引用
- Fukumitsu N, Shiba S, Shibuya K, et al. Comprehensive Analysis of Data From a Nationwide Japanese Cohort on Particle Therapy for Metastatic Liver Tumors. Int J Radiat Oncol Biol Phys. 2025. PMID: 40720997. doi:10.1016/j.ijrobp.2025.07.1433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。